GGrantIndex
← Leaderboards

John James Letterio

Case Western Reserve University

Google Scholar ↗PubMed ↗ORCID ↗
$5,630,711
Attributed
$6,682,132
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY2008–25
$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,682,132 · 10

By mechanism

R01$5,191,614 · 3
R21$793,184 · 2
P30$540,438 · 4
R03$156,896 · 1

Top collaborators

Most similar at Case Western Reserve University

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsInhibitor/AntagonistSignal TransductionResistanceLaboratoriesTumorCellsMediatingRelapsePathway InteractionsNovel StrategiesResponseScientistInflammationImmuneInflammatoryPreventMouse ModelResearch PersonnelCytokineColonNovel TherapeuticsBrainMutation

Grant awards (29)

Development of a novel, CNS-penetrant synthetic triterpenoid for pediatric high-grade glioma.$188,169
R21 · FY2025 · CA · contact PI
Developmental Therapeutics$85,361
P30 · FY2025 · CA · contact PI
Development of a novel, CNS-penetrant synthetic triterpenoid for pediatric high-grade glioma.$225,803
R21 · FY2024 · CA · contact PI
Developmental Therapeutics Research Program$93,151
P30 · FY2024 · CA · contact PI
Developmental Therapeutics Research Program$93,151
P30 · FY2023 · CA · contact PI
Developmental Therapeutics Research Program$55,090
P30 · FY2022 · CA · contact PI
Developmental Therapeutics Research Program$53,112
P30 · FY2021 · CA · contact PI
Developmental Therapeutics Research Program$51,030
P30 · FY2020 · CA · contact PI
Developmental Therapeutics Research Program$49,491
P30 · FY2019 · CA · contact PI
Developmental Therapeutics Research Program$50,794
P30 · FY2018 · CA · contact PI
Developmental Therapeutics Research Program$9,258
P30 · FY2018 · CA · contact PI
CdK5, OX40, and Immune Tolerance in Uveitis$396,592
R01 · FY2017 · EY · contact PI
Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention$328,888
R01 · FY2017 · CA · contact PI
CdK5, OX40, and Immune Tolerance in Uveitis$396,592
R01 · FY2016 · EY · contact PI
Novel mechanisms of immune activation following allogeneic, hematopoietic stem ce$396,250
R01 · FY2016 · HL · contact PI
Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention$328,888
R01 · FY2016 · CA · contact PI
Cdk5 signaling in ICN1-induced T Cell Leukemogenesis$172,369
R21 · FY2016 · CA
CdK5, OX40, and Immune Tolerance in Uveitis$392,180
R01 · FY2015 · EY · contact PI
Novel mechanisms of immune activation following allogeneic, hematopoietic stem cell transplantation$390,305
R01 · FY2015 · HL · contact PI
Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention$328,888
R01 · FY2015 · CA · contact PI
Cdk5 signaling in ICN1-induced T Cell Leukemogenesis$206,843
R21 · FY2015 · CA
CdK5, OX40, and Immune Tolerance in Uveitis$392,181
R01 · FY2014 · EY · contact PI
Novel mechanisms of immune activation following allogeneic, hematopoietic stem ce$388,325
R01 · FY2014 · HL · contact PI
Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention$319,021
R01 · FY2014 · CA · contact PI
CdK5, OX40, and Immune Tolerance in Uveitis$413,539
R01 · FY2013 · EY · contact PI
Novel mechanisms of immune activation following allogeneic, hematopoietic stem ce$391,855
R01 · FY2013 · HL · contact PI
Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention$328,110
R01 · FY2013 · CA · contact PI
DISCOVERY AND EVALUATION OF NOVEL TRITERPENOID CHEMOPREVENTIVES IN A NEW COLON CA$78,500
R03 · FY2009 · CA
DISCOVERY AND EVALUATION OF NOVEL TRITERPENOID CHEMOPREVENTIVES IN A NEW COLON CA$78,396
R03 · FY2008 · CA